SCHEMBL10285462

SCHEMBL10285462

Cc1ccccc1-c1nc2ccc(F)c(F)c2nc1CN

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.39
PIK3CD O00329 2/20 0.38
ADORA2A P29274 1/20 0.37
MBNL1 Q9NR56 1/20 0.37
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
GAA P10253 2/20 0.35
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
DPP8 Q6V1X1 1/20 0.34
MAPK14 Q16539 2/20 0.33
MAPK13 O15264 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169580 0.84 DPP4 (0.40) DPP4PIK3CDRAB9ANPC1SMN1; SMN2
SCHEMBL10286259 0.82 RAB9A (0.52) DPP4PIK3CDADORA2ARAB9ANPC1
SCHEMBL4174475 0.79 DPP4 (0.40) DPP4RAB9ANPC1ALDH1A1GAA
SCHEMBL10286273 0.76 RAB9A (0.52) DPP4PIK3CDADORA2ARAB9ANPC1
SCHEMBL19788607 0.74 DPP4 (0.39) DPP4PIK3CDGAAMGAMSI
SCHEMBL21705888 0.74 MBNL1 (0.39) DPP4PIK3CDADORA2AMBNL1RAB9A
SCHEMBL4174724 0.72 PIK3CD (0.52) DPP4PIK3CDRAB9ANPC1ALDH1A1
SCHEMBL13973988 0.72 MBNL1 (0.43) PIK3CDADORA2AMBNL1RAB9ANPC1
SCHEMBL4174814 0.71 KDM4E (0.37) DPP4PIK3CDRAB9ANPC1SMN1; SMN2
SCHEMBL4179102 0.69 DPP4 (0.40) DPP4PIK3CDADORA2AMBNL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137581-A1 Heterocyclic compounds and their uses MCL1, BCL9, MALT1 DPP4 4588/4885PIK3CD 16/4885ADORA2A 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.